Evidence map›Paper›PMID 39670471›Full record

ArticleParasitology2025

Repurposing statins for the treatment of larval cestodiases:

Marina Monteiro Guedes, Jeferson Camargo de Lima, Jéssica Andrade Paes, María Del Pilar Cevasco Contreras, Ana María Celentano, Arnaldo Zaha, Karina Mariante Monteiro, Mara Cecilia Rosenzvit, Henrique Bunselmeyer Ferreira

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Parasitology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marina Monteiro GuedesPrograma de Pós-Graduação em Biologia Celular e Molecular, Centro de Biotecnologia (CBiot), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
Jeferson Camargo de LimaPrograma de Pós-Graduação em Biologia Celular e Molecular, Centro de Biotecnologia (CBiot), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
Jéssica Andrade PaesPrograma de Pós-Graduação em Biologia Celular e Molecular, Centro de Biotecnologia (CBiot), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
María Del Pilar Cevasco ContrerasDepartamento de Microbiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1113AAD, Argentina.
Ana María CelentanoDepartamento de Microbiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1113AAD, Argentina.
Arnaldo ZahaPrograma de Pós-Graduação em Biologia Celular e Molecular, Centro de Biotecnologia (CBiot), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
Karina Mariante MonteiroPrograma de Pós-Graduação em Biologia Celular e Molecular, Centro de Biotecnologia (CBiot), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
Mara Cecilia RosenzvitDepartamento de Microbiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1113AAD, Argentina.
Henrique Bunselmeyer FerreiraPrograma de Pós-Graduação em Biologia Celular e Molecular, Centro de Biotecnologia (CBiot), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.ORCID https://orcid.org/0000-0003-3611-6040

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 428305/2018-0Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul 24/2551-0001275-3
6 · The paper itself

Abstract

Cestodiases, like echinococcoses and cysticercoses, represent a global health problem. Currently available anthelmintics, as benzimidazoles and praziquantel, have limited effectiveness against these cestodiases, creating a demand for the identification of new and more effective drugs. Here, the potential of statins (simvastatin and fluvastatin), for repositioning as novel anthelmintic is explored. Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a main enzyme in the mevalonate pathway, which is vital for the synthesis of non-steroidal isoprenoids and the maintenance of normal cell functioning. A survey for HMG-CoA reductase encoding genes showed that they are present in a single copy in the genomes of parasitic helminths and their mammal hosts. Sequence alignments and phylogenetic analyses showed 20-95% overall identities among ortholog HMG-CoA reductases, with special conservation of their catalytic domains. The HMG-CoA reductase 3D-structure was predicted for orthologs from 3 cestodes of medical importance (

Indexed as

AnthelminticsCestodaDrug RepositioningHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesAnimalsComputer SimulationFluvastatinLarvaMolecular Docking SimulationPhylogenySequence AlignmentSimvastatinAnthelminticsFluvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesSimvastatindrug repurposingEchinococcus granulosusEchinococcus multilocularisMesocestoides cortiMevalonate pathwaystatinsTaenia solium

Identifiers

PMID39670471
PMCPMC12644962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.